-+ 0.00%
-+ 0.00%
-+ 0.00%

Rezolute publishes corporate presentation on ersodetug treatment for hyperinsulinism hypoglycemia

PUBT·05/01/2026 16:26:01
Listen to the news
Rezolute publishes corporate presentation on ersodetug treatment for hyperinsulinism hypoglycemia
  • Rezolute outlined plans to advance ersodetug (RZ358), an antibody targeting hypoglycemia across congenital hyperinsulinism and tumor-related hyperinsulinism.
  • Phase 3 sunRIZE study in congenital hyperinsulinism missed primary endpoint and key secondary glucose endpoints, with reductions in hypoglycemia not statistically different from placebo.
  • Safety profile showed no limiting findings, with four early discontinuations tied to hypersensitivity, infusion reaction, or mild hypertrichosis.
  • Pipeline timeline targets tumor hyperinsulinism Phase 3 topline data in 2H 2026.
  • Rezolute reported $133 million cash, projecting runway to mid-2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.